Disease-Modifying  Digital Therapeutics (DTx) for MS Patients

Thank you for visiting our presentation at the CMSC annual meeting 2022!

For up to 70% of MS patients, fatigue is listed as the most disabling symptom associated with their disease. To date, there are no effective pharmacological fatigue treatments available. For these patients and for their physicians, we developed elevida, a CBT-based digital therapeutic against MS-fatigue. 

elevida has been clinically proven to effectively reduce MS fatigue symptoms¹. Take a closer look here:

Get in touch with us

If you are interested in working with us as a research partner or if you want to learn more about our disease-modifying DTx for MS patients, contact us:

Catch us at ECTRIMS 2022

Don’t miss seeing us in person at another big event this fall: the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis! We will be attending alongside our research partners, including the National MS Society, to share some exciting news related to disease-modifying DTx for MS Patients.

Who we are

GAIA AG is the worldwide leader in the development of evidence-based, safe and accessible digital therapeutics. GAIA'S DTx solutions offer the same effect sizes, similar safety profiles and equal levels of convenience as found in well-developed pharmaceutical solutions.

For more than 25 years we have been combining scientific, technological and therapeutic expertise under one roof. Our mission is to increase the quality of people’s wellbeing by helping them to restore and maintain their mental and physical health. The effectiveness of our products has been clinically proven in more than 20 RCTs and 2 meta-analyses.

Intended Purpose

elevida is intended to provide therapeutic methods and exercises based on evidence-based psychological and psychotherapeutic therapies for patients with Multiple Sclerosis (MS) and comorbid fatigue (persistent tiredness respectively exhaustion), to help them manage their fatigue. elevida is intended as a self-application supplemental to care-as-usual for patients 18 years of age or older. elevida is neither intended to replace treatment provided by a health care provider nor to provide information which is used to take decisions with diagnosis or therapeutic purposes.